The Global Myocardial Infarction Market is estimated to be valued at US$ 1,816.8 Mn in 2023 and is expected to exhibit a CAGR of 5.9 % over the forecast period from 2021 to 2028, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Myocardial infarction, also known as a heart attack, occurs due to rupture or disruption of atherosclerotic plaque in the coronary arteries which can lead to reduced oxygen delivery and potential damage to heart muscles. Heart attacks require timely medical help to reduce mortality and long term damage. Treatment strategies include angioplasty, stents and drugs.
Market key trends:
One of the key trends in the myocardial infarction market is the rise in drug eluting stents. Drug eluting stents are designed to slowly release medications like rapamycin or paclitaxel inside arteries. This prevents renarrowing of arteries post angioplasty. They are more effective than bare metal stents and help reduce need for repeat procedures. Their adoption has increased significantly owing to better clinical outcomes and are expected to witness strong demand over the forecast period.
Segment Analysis
The global myocardial infarction market is segmented into drug class and distribution channel. Based on drug class, the market is segmented into antiplatelet agents, glycoprotein IIb/IIIa inhibitors, anticoagulants, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, analgesics, and others. The antiplatelet agents segment dominates the market and is expected to continue its dominance over the forecast period. Antiplatelet agents help in preventing blood clots and reduce the risk of heart attacks and strokes. Their widespread use as the first line treatment of myocardial infarction drives the growth of this segment.
Key Takeaways
The Global Myocardial Infarction Market size is expected to reach US$ 1,816.8 Mn in 2021 and exhibit a CAGR of 5.9% over the forecast period due to the increasing prevalence of cardiovascular diseases.
The market size related content comprises:
The global myocardial infarction market is expected to witness high growth, exhibiting a CAGR of 5.9% over the forecast period, due to increasing prevalence of cardiovascular diseases. According to the World Health Organization, cardiovascular diseases are the number one cause of death globally, taking an estimated 17.9 million lives each year. The rising geriatric population which is more susceptible to heart diseases also contributes to the growth of the myocardial infarction market.
Regional analysis related content comprises:
Geographically, the North American region dominates the myocardial infarction market and is expected to continue its dominance over the forecast period. This is attributed to the growing number of people suffering from obesity, high cholesterol, and unhealthy lifestyles in the US and Canada. Europe is the second largest market driven by rising awareness about cardiovascular diseases. The Asia Pacific region is expected to exhibit the fastest growth rate owing to the growing aging population and adoption of sedentary lifestyle in developing countries like India and China.
Key players related content comprises:
Key players operating in the myocardial infarction market are Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA. These players are focusing on developing novel drugs and efficient treatment options to strengthen their market position.
The Global Myocardial Infarction Market is estimated to be valued at US$ 1,816.8 Mn in 2023 and is expected to exhibit a CAGR of 5.9 % over the forecast period from 2021 to 2028, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Myocardial infarction, also known as a heart attack, occurs due to rupture or disruption of atherosclerotic plaque in the coronary arteries which can lead to reduced oxygen delivery and potential damage to heart muscles. Heart attacks require timely medical help to reduce mortality and long term damage. Treatment strategies include angioplasty, stents and drugs.
Market key trends:
One of the key trends in the myocardial infarction market is the rise in drug eluting stents. Drug eluting stents are designed to slowly release medications like rapamycin or paclitaxel inside arteries. This prevents renarrowing of arteries post angioplasty. They are more effective than bare metal stents and help reduce need for repeat procedures. Their adoption has increased significantly owing to better clinical outcomes and are expected to witness strong demand over the forecast period.
Segment Analysis
The global myocardial infarction market is segmented into drug class and distribution channel. Based on drug class, the market is segmented into antiplatelet agents, glycoprotein IIb/IIIa inhibitors, anticoagulants, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, analgesics, and others. The antiplatelet agents segment dominates the market and is expected to continue its dominance over the forecast period. Antiplatelet agents help in preventing blood clots and reduce the risk of heart attacks and strokes. Their widespread use as the first line treatment of myocardial infarction drives the growth of this segment.
Key Takeaways
The Global Myocardial Infarction Market size is expected to reach US$ 1,816.8 Mn in 2021 and exhibit a CAGR of 5.9% over the forecast period due to the increasing prevalence of cardiovascular diseases.
The market size related content comprises:
The global myocardial infarction market is expected to witness high growth, exhibiting a CAGR of 5.9% over the forecast period, due to increasing prevalence of cardiovascular diseases. According to the World Health Organization, cardiovascular diseases are the number one cause of death globally, taking an estimated 17.9 million lives each year. The rising geriatric population which is more susceptible to heart diseases also contributes to the growth of the myocardial infarction market.
Regional analysis related content comprises:
Geographically, the North American region dominates the myocardial infarction market and is expected to continue its dominance over the forecast period. This is attributed to the growing number of people suffering from obesity, high cholesterol, and unhealthy lifestyles in the US and Canada. Europe is the second largest market driven by rising awareness about cardiovascular diseases. The Asia Pacific region is expected to exhibit the fastest growth rate owing to the growing aging population and adoption of sedentary lifestyle in developing countries like India and China.
Key players related content comprises:
Key players operating in the myocardial infarction market are Bristol-Myers Squibb Co., Bayer AG, Johnson & Johnson Services Inc., Sanofi S.A., Novartis International AG, AstraZeneca plc., Daiichi Sankyo Co Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc., and Merck KGaA. These players are focusing on developing novel drugs and efficient treatment options to strengthen their market position.
Comments
0 comment